Why scientists are increasingly studying light and sound therapy for Alzheimer’s patients
A small MIT clinical study is turning heads in dementia research. Scientists gave five people with mild Alzheimer’s disease daily doses of flickering light and pulsing sound therapy at 40 Hz for two years, and the results in three of them suggest a noninvasive brain stimulation approach may help slow the disease in some patients. For families watching a loved one fade, that possibility carries weight.
The findings, published in Alzheimer’s & Dementia and reported by MIT, are early. But they add fresh data to a growing effort that treats Alzheimer’s as an electrical problem in the brain, not just a molecular one.
How 40 Hz Sound Therapy Works
The treatment is called GENUS, short for gamma entrainment using sensory stimuli. Patients wear or sit in front of a device that delivers flashing light and clicking sound at 40 cycles per second. That frequency is meant to drive gamma-wave activity in the brain, a rhythm tied to memory and cognition that weakens in people with dementia.
In the MIT pilot, five patients with mild Alzheimer’s used the setup daily for two years. No adverse events occurred. Three female participants with late-onset Alzheimer’s kept strong EEG entrainment and showed less decline on the Mini-Mental State Examination, the Clinical Dementia Rating and the Functional Assessment Scale than matched patients from the National Alzheimer’s Coordinating Center, the Alzheimer’s Disease Neuroimaging Initiative and the Longitudinal Early-Onset Alzheimer’s Disease Study.
Two participants also gave plasma samples. Both showed drops in pTau217, a blood biomarker linked to Alzheimer’s progression, of 47% and 19%.
“We found that daily 40Hz audiovisual stimulation over two years is safe, feasible and may slow cognitive decline and biomarker progression, especially in late-onset AD patients,” the authors wrote.
Why the Results Are Mixed
Not everyone benefited. The two male participants in the study, both with early-onset forms of the disease, did not show significant improvements after two years. That split has researchers cautious about overreach.
The dataset is tiny, and the authors are clear that further investigation is needed before anyone calls this a treatment. Still, it is the longest-running test of the noninvasive method so far. A larger nationwide clinical trial is being run by Cognito Therapeutics, an MIT spinoff.
Other Researchers Exploring Light and Sound
At Georgia Tech and Emory University, associate professor Annabelle Singer is running a parallel line of research using something that looks like ski goggles paired with headphones. Patients see flickering lights faster than a standard strobe and hear rapid clicking tones.
“We are taking a really different approach to Alzheimer’s,” Singer told CNN. “We’ve determined how neural activity that is essential for memory fails in Alzheimer’s disease. We’re then using that information to develop brain stimulation that could improve brain health.”
She is careful about what the approach can promise. “We don’t know that we can reverse the memory impairment that’s already there. Instead, what we’re going for is to slow the continuing decline.”
Her framing reflects a shift in the field. “The majority of research on Alzheimer’s disease focuses on the molecular scale, how proteins accumulate or go wrong,” Singer said. “We’re asking, how do neurons behave electrically to generate memory and how do those patterns change in Alzheimer’s patients?”
What Earlier Trials Found
Two earlier studies laid the groundwork. In a phase 1 trial reported by the Alzheimer’s Research Association, 43 participants, including 16 with early-stage Alzheimer’s and two epilepsy patients preparing for brain surgery, received brief sessions of the 40 Hz treatment. Gamma-wave strength rose across brain regions during therapy, and sleepiness was the most common side effect.
In a phase 2a trial, 15 patients used GENUS devices at home for an hour a day for at least three months. Half got the real treatment and half got a sham of white noise and steady light. The treatment group scored better on a face-name memory test and showed stronger connections between cognitive and visual-processing regions. Two measures tied to Alzheimer’s progression, hippocampal shrinkage and ventricle expansion, worsened in the control group but held steady in the treatment group.
What It Means for Patients Now
Sound therapy is not an approved Alzheimer’s treatment. The studies so far involve small groups, and the pilot results split along sex and disease-onset lines that researchers cannot yet explain. Anyone considering an at-home device should talk with a physician first and be wary of products that overstate the science.
What the research does offer is a plausible, low-risk direction worth watching. For a disease with few effective options, a daily hour of light and sound that appears safe over two years is a lead the field is not ready to drop.
This article was created by content specialists using various tools, including AI.
